11:53 AM EDT, 06/23/2025 (MT Newswires) -- The European stock markets closed lower in Monday trading as The Stoxx Europe 600 lost 0.19%, Germany's DAX was down 0.33%, the FTSE 100 was off 0.14%, France's CAC 40 slid 0.67%, and the Swiss Market Index declined 0.10%.

The seasonally-adjusted HCOB Flash Composite PMI Output Index, which gauges the health of European manufacturing remained unchanged at 50.2 in June from May and registered above the 50 threshold indicating expansion for a sixth straight month. However, the expansion of business activity continues to be marginal.

In the UK, the S&P Global UK Consumer Sentiment Index edged lower in June to 45.0 from 45.2 in May. The index indicated that British households are still experiencing a decline in their financial health.

And in corporate news, HSBC is weighing plans to bring more employees back to offices, a move that could raise its real estate costs by about $200 million annually, Bloomberg reported Monday, citing people familiar with the matter. HSBC did not immediately respond to MT Newswires' request for comment.

Getty Images' proposed merger with Shutterstock has attracted potential scrutiny by the UK Competition and Markets Authority. The antitrust regulator said Monday it is considering whether the deal would lead to the creation of a "relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the [UK] for goods or services."

Getty Images and Shutterstock did not immediately respond to MT Newswires' requests for comment.

British pharmaceutical company GSK said Monday that the European Medicines Agency has accepted for review the marketing authorization application for its experimental drug, linerixibat, to treat cholestatic pruritus in patients with primary biliary cholangitis, a rare autoimmune liver condition.

Shares of GSK edged 0.05% lower on the FTSE in Monday trading.

Novo Nordisk said Sunday that participants with obesity in a phase 3 study met its primary endpoint of greater weight loss with a higher 7.2mg dose of Wegovy. The Danish pharmaceutical giant also said Sunday that its phase 3 trial evaluating CagriSema for weight loss in overweight or obese adults without diabetes, met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss compared to placebo.

Shares of Novo Nordisk fell 5.3% in Copenhagen.